

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended

CT Healthcare Trust plc (the "Company")

Results of Quarterly Tender Offer

LEI: 213800HQ3J3H9YF2UI82

2 September 2026

Further to the quarterly tender offer launched by the Company on 6 August 2026 (the "**Tender Offer**") for up to 15 per cent. of the Company's issued Shares (excluding any Shares held in treasury), the Company today announces:

- that 3,885,283 Shares were validly tendered pursuant to the Tender Offer, equal to approximately 8.37 per cent. of the 46,432,942 Shares in issue (excluding any Shares held in treasury); and
- that at the General Meeting held at 11.00 a.m. today at the offices of Columbia Threadneedle, 78 Cannon Street, London EC4N 6AG on 2 September 2026, each of the resolutions proposed was duly passed on a poll.

The maximum number of Shares to be acquired under the Tender Offer is 6,998,907 Shares, representing 15 per cent. of the Shares in issue (excluding any Shares held in treasury) as at 5 August 2026, being the latest practicable date prior to the publication of the Circular (the "**Available Shares**").

Accordingly, Eligible Shareholders who validly tendered a percentage of their Shares equal to or less than their Basic Entitlement shall have all tendered Shares purchased in full under the Tender Offer and Eligible Shareholders who validly tendered a percentage of Shares greater than their Basic Entitlement will have an amount of Shares equal to their Basic Entitlement purchased in full plus 100 per cent. of their Excess Applications (if any), in accordance with the process described in the circular announcing the Tender Offer (the "**Circular**").

After taking account of the rounding down of each valid applicant's participation to the nearest whole Share, the Company will purchase in aggregate 3,885,283 Shares under the Tender Offer.

The price at which tendered Shares will be purchased (the "**Tender Price**") will be equal to the prevailing Net Asset Value per Share as at the Calculation Date of 1 September 2026 less the Tender Offer Expenses per Share. The final Tender Price for successfully tendered Shares will be announced later today.

The results of the resolutions proposed at the General Meeting, each of which was held by poll, were as follows:

Ordinary Resolution	In favour*	% shares voted in favour	Against	% shares voted against	Votes withheld**
To approve the sale of Shares under the Matching Facility at a price less than prevailing NAV per Share	14,780,127	99.39	90,352	0.61	81,931
Special Resolution	In favour*	% shares voted in favour	Against	% shares voted against	Votes withheld**
To approve the repurchase of Shares pursuant to the Tender Offer	14,784,715	99.42	85,764	0.58	81,931

* Votes for include discretionary votes

** A vote withheld is a not a vote in law and is not counted in the votes for or against a resolution

The full text of the resolutions can be found in the Circular which is available for inspection at the National Storage Mechanism <https://data.fca.org.uk/#/nsm/nationalstoragemechanism> and also on the Company's website www.cthealthcaretrust.co.uk.

Terms used and not otherwise defined in this announcement shall have the meanings given to them in the Circular.

For further information, please contact:

CT Healthcare Trust plc

Sarah MacAulay, Chairman

Columbia Threadneedle Investments **+44 (0) 207 464 5000**

Marrack Tonkin, Head of
Investment Trusts

JP Morgan Cazenove **+44 (0) 20 3493 8000**

William Simmonds / Rupert
Budge

Company Secretary

Columbia Threadneedle Investments **+44 (0) 131 573 8372**

Scott McEllen

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TENMZGGLMZKGVZM